Breaking News Instant updates and real-time market news.

NVS

Novartis

$83.78

-0.29 (-0.34%)

05:28
08/29/18
08/29
05:28
08/29/18
05:28

EC approves Novartis combination therapy Tafinlar + Mekinist

Novartis announced that the European Commission has approved Tafinlar in combination with Mekinist for the adjuvant treatment of stage III patients with BRAF V600 mutation-positive melanoma after complete surgical resection. This approval is the third for Tafinlar in combination with Mekinist in Europe across a variety of tumor types identified with a high level of BRAF mutation. It also demonstrates Novartis leadership in BRAF+ targeted therapy, and to date, more than 60,000 patients worldwide have been treated with the combination therapy across four indications.

  • 12

    Sep

NVS Novartis
$83.78

-0.29 (-0.34%)

08/07/18
STFL
08/07/18
INITIATION
Target $30
STFL
Buy
Alder Biopharmaceuticals initiated with a Buy at Stifel
Stifel analyst Paul Matteis initiated coverage of Alder BioPharmaceuticals with a Buy rating and $30 price target, calling it an attractive, differentiated "pure play" within the migraine antiCGRP prevention market. While Matteis acknowledges it "won't be easy" for Alder to compete with Amgen (AMGN), Novartis (NVS), Eli Lilly (LLY) and Teva (TEVA), he believes the unique profile of eptinezumab remains underappreciated and may allow it to capture meaningful, above consensus share of a large, emerging drug category.
08/13/18
PIPR
08/13/18
NO CHANGE
PIPR
Overweight
Regeneron should be bought on 'largely meaningless' CRL, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond recommends buying shares of Regeneron Pharmaceuticals on weakness after the company received a Complete Response Letter from the FDA regarding Eylea's supplemental Biologics License Application for Q12W dosing in wet macular degeneration. The CRL is "largely meaningless" as this label expansion is almost entirely a defensive move by Regeneron to counter potential Q12W labeling by competitor Novartis' (NVS) RTH258, Raymond tells investors in a research note. The analyst has "reasonable confidence" that approval for this label will come within two months. He keeps an Overweight rating on shares of Regeneron.
08/16/18
08/16/18
DOWNGRADE

Hold
AstraZeneca downgraded to Hold following outperformance at Jefferies
As previously reported, Jefferies analyst Ian Hilliker downgraded AstraZeneca (AZN) to Hold from Buy citing valuation following the stock's outperformance since he upgraded it in March. Hilliker has raised his price target on AstraZeneca to 6,200p, but notes that this only leaves about 8% of further upside. Following results for the Q2 period, Hilliker said Novartis (NVS) remains his top European Pharmaceuticals pick, followed by Roche (RHHBY) and GlaxoSmithKline (GSK) in third place.
08/23/18
MSCO
08/23/18
NO CHANGE
Target $45
MSCO
Overweight
Pfizer price target raised to $45 from $43 at Morgan Stanley
Morgan Stanley analyst David Risinger maintained an Overweight rating on Pfizer (PFE) and raised his price target to $45 based upon a 5-year CAGR for revenue growth of 3% and EPS growth of 7%. In a research note to investors, Risinger says he believes the primary driver of major pharma stock performance in recent months is "defensive rotation." Additionally, he notes that political news has been "encouraging" as of late, with President Trump tweeting on July 19 "Thank you to Novartis (NVS) for not increasing your prices on prescription drugs. Likewise to Pfizer." Looking ahead, the analyst says to watch for U.S. pricing perception drivers in the coming months that could impact pharma stock performance, including potential additional HHS action on drug rebates, November election results and manufacturer communication and action on U.S. list prices by early January.

TODAY'S FREE FLY STORIES

02:40
12/13/18
12/13
02:40
12/13/18
02:40
General news
FX Update: A risk-on theme has been coursing through forex markets »

FX Update: A risk-on…

01:45
12/13/18
12/13
01:45
12/13/18
01:45
General news
Asian Market Wrap: »

Asian Market Wrap:…

BHVN

Biohaven Pharmaceutical

$37.72

1.02 (2.78%)

20:51
12/12/18
12/12
20:51
12/12/18
20:51
Syndicate
Biohaven Pharmaceutical 3.3M share Secondary priced at $37.25 per share »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

FIVE

Five Below

$101.38

1.86 (1.87%)

20:48
12/12/18
12/12
20:48
12/12/18
20:48
Upgrade
Five Below rating change at Goldman Sachs »

Five Below upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRNS

Marinus Pharmaceuticals

$4.21

-0.89 (-17.45%)

20:28
12/12/18
12/12
20:28
12/12/18
20:28
Syndicate
Marinus Pharmaceuticals 12M share Secondary priced at $3.75 per share »

Jefferies and Leerink are…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

UNM

Unum Group

$30.27

-0.04 (-0.13%)

20:25
12/12/18
12/12
20:25
12/12/18
20:25
Hot Stocks
Unum Group sees FY19 adjusted EPS growth of 4%-7% »

Sees FY19 tax rate of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

CIEN

Ciena

$32.14

0.535 (1.69%)

20:25
12/12/18
12/12
20:25
12/12/18
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

TDC

Teradata

$38.02

0.65 (1.74%)

20:18
12/12/18
12/12
20:18
12/12/18
20:18
Hot Stocks
Teradata targets 2021 recurring revenue growth of 14% »

Also sees 2021 gross…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 19

    Dec

  • 20

    Dec

HESM

Hess Midstream Partners

$19.43

0.38 (1.99%)

19:09
12/12/18
12/12
19:09
12/12/18
19:09
Hot Stocks
Hess Midstream Partners sees FY19 adjusted EBITDA $550M-$575M »

Sees FY19: net income…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TOCA

Tocagen

$11.22

-1.63 (-12.68%)

19:05
12/12/18
12/12
19:05
12/12/18
19:05
Syndicate
Tocagen 3M share Secondary priced at $10.00 per share »

Citi and Leerink are…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

ALL

Allstate

$82.37

-0.12 (-0.15%)

19:03
12/12/18
12/12
19:03
12/12/18
19:03
Hot Stocks
Allstate announces estimated November catastrophe losses of $685M »

Allstate announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XOM

Exxon Mobil

$76.04

-0.64 (-0.83%)

19:01
12/12/18
12/12
19:01
12/12/18
19:01
Hot Stocks
Exxon makes final investment decision to develop West Barracouta gas project »

ExxonMobil said that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NDSN

Nordson

$111.83

1.09 (0.98%)

, JCS

Communications Systems

$2.42

0.2 (9.01%)

19:00
12/12/18
12/12
19:00
12/12/18
19:00
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS:…

NDSN

Nordson

$111.83

1.09 (0.98%)

JCS

Communications Systems

$2.42

0.2 (9.01%)

BW

Babcock & Wilcox

$0.77

0.0569 (7.94%)

FIVE

Five Below

$101.38

1.86 (1.87%)

BABA

Alibaba

$151.49

-0.34 (-0.22%)

TLRD

Tailored Brands

$20.16

0.32 (1.61%)

LLNW

Limelight Networks

$3.20

0.025 (0.79%)

OXM

Oxford Industries

$74.88

0.895 (1.21%)

AGTC

Applied Genetic

$6.61

0.54 (8.90%)

VBIV

VBI Vaccines

$1.66

0.08 (5.06%)

HASI

Hannon Armstrong

$23.10

-0.16 (-0.69%)

BVN

Buenaventura

$15.25

0.22 (1.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 12

    Dec

  • 12

    Dec

  • 12

    Dec

  • 13

    Dec

  • 04

    Mar

  • 12

    Mar

  • 13

    Dec

  • 13

    Dec

OXM

Oxford Industries

$74.88

0.895 (1.21%)

18:58
12/12/18
12/12
18:58
12/12/18
18:58
Earnings
Oxford Industries cuts FY18 EPS view to $4.20-$4.35 from $4.45-$4.65 »

Cuts FY18 revenue view to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

OXM

Oxford Industries

$74.88

0.895 (1.21%)

18:56
12/12/18
12/12
18:56
12/12/18
18:56
Earnings
Oxford Industries sees Q4 EPS 96c-$1.11 vs. 93c last year »

Sees Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

OXM

Oxford Industries

$74.88

0.895 (1.21%)

18:55
12/12/18
12/12
18:55
12/12/18
18:55
Earnings
Oxford Industries reports Q3 adjusted EPS 14c vs. 17c last year »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

NEXT

NextDecade

$4.74

0.04 (0.85%)

18:30
12/12/18
12/12
18:30
12/12/18
18:30
Hot Stocks
NextDecade's Rio Grande LNG project approved by TCEQ »

NextDecade Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UAL

United Continental

$89.63

1.49 (1.69%)

18:15
12/12/18
12/12
18:15
12/12/18
18:15
Periodicals
United CEO seeks to boost flight network by 4%-6% next year, Reuters says »

United Airlines CEO Oscar…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Mar

AKAO

Achaogen

$1.80

0.06 (3.45%)

17:58
12/12/18
12/12
17:58
12/12/18
17:58
Hot Stocks
Breaking Hot Stocks news story on Achaogen »

Robert Duggan raises…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FLR

Fluor

$34.11

0.29 (0.86%)

17:56
12/12/18
12/12
17:56
12/12/18
17:56
Hot Stocks
Fluor announces participation in $2.1B rail project in Chicago »

Fluor announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FIVE

Five Below

$101.38

1.86 (1.87%)

17:55
12/12/18
12/12
17:55
12/12/18
17:55
Upgrade
Five Below rating change at Goldman Sachs »

Five Below upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BTC

Bitcoin

$0.00

(0.00%)

, BITCOIN

Bitcoin

$0.00

(0.00%)

17:49
12/12/18
12/12
17:49
12/12/18
17:49
Hot Stocks
SEC says former execs behind allegedly fraudulent ICO settle scam charges »

Two former executives…

BTC

Bitcoin

$0.00

(0.00%)

BITCOIN

Bitcoin

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PK

Park Hotels & Resorts

$29.28

0.08 (0.27%)

17:44
12/12/18
12/12
17:44
12/12/18
17:44
Hot Stocks
Park Hotels & Resorts announces Q4 dividend of $1.00 per share »

Park Hotels & Resorts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PK

Park Hotels & Resorts

$29.28

0.08 (0.27%)

17:44
12/12/18
12/12
17:44
12/12/18
17:44
Hot Stocks
Park Hotels & Resorts announces Q4 dividend of $1.00 per share »

Park Hotels & Resorts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNP

CenterPoint Energy

$28.90

0.12 (0.42%)

17:37
12/12/18
12/12
17:37
12/12/18
17:37
Hot Stocks
CenterPoint Energy raises dividend 4% to 28.75c per share »

The company's board…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.